The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

A panel of outside FDA advisers will be asked what types of studies should be conducted in order to evaluate the safety of diabetes’ drugs Avandia and Actos, both of which have been linked to cardiac problems. Just last year, the FDA suggested the drugs should carry the highest possible warning labels.

“Questions have been raised as to whether long-term cardiovascular trials should be part of the approval process for pharmacological therapies developed for the treatment of diabetes,” according to the FDA briefing document, prepared for the panel’s meeting. “

Comments are closed.

Of Interest